BGM Group Ltd. (BGM)
$10.48+2.75%Close
BUYRECOVERY · day 9
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $2.1B
- Beta
- 1.87
- P/E (TTM)
- -2.17
- Short % float
- 3.96%
- Days to cover
- 1.5
- SI change
- +86.0%
- 1W
- +8.60%
- 1M
- +37.17%
- vs SPY 1W
- +8.74%
- vs SPY 1M
- +34.67%
Industry peers
FMP comparable companies · ranked by market cap
- TWSTSELLTwist Bioscience Corporation$9.9BCRISISQ 30$159.78-0.35%
- EWTXSELLEdgewise Therapeutics, Inc.$4.2BCRISISQ 15$39.06-5.64%
- CLOVBUYClover Health Investments, Corp.$2.5BRECOVERYQ 7$4.79+0.63%
- AVDLAvadel Pharmaceuticals plc$2.1B$21.64
- MESOSELLMesoblast Limited$1.9BRECOVERYQ 19$14.29-2.59%
- ANIPSELLANI Pharmaceuticals, Inc.$1.7BRECOVERYQ 9$73.89-3.74%
- PAHCBUYPhibro Animal Health Corporation$1.6BRECOVERYQ 10$38.30-1.66%
- GPCRSELLStructure Therapeutics Inc.$1.5BCRISISQ 12$25.54-6.69%
- PRCTSELLPROCEPT BioRobotics Corporation$1.0BRECOVERYQ -2$18.40-2.40%
- QDELBUYQuidelOrtho Corporation$915MRECOVERYQ 8$13.42+6.42%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 5
- GROWTH
- 29
- GARP
- 3
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-3.2%
REV YoY-
ROE-5.4%
EPS YoY-
ROA-4.9%
GROSS13
OP-23
NET-44
[VALUATION]
P/E TTM-2.17
P/E FWD-
SECTOR PE20.34
INDUSTRY PE19.31
P/B0.16
P/FCF-
EV/EBITDA-13.26
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E0.30
ALTMAN Z-
CURR RATIO1.25
ND/EBITDA-
BETA1.87
Company news
FAQ
- What is LOPJLB’s current signal on BGM?
- LOPJLB’s latest quantitative signal on BGM Group Ltd. (BGM) is BUY in a RECOVERY regime. Signals are updated daily.
- What market regime is BGM in?
- BGM Group Ltd. (BGM) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does BGM Group Ltd. (BGM) do?
- Operating from Chengdu, People's Republic of China, BGM Group Ltd. engages in the manufacturing and supply of active pharmaceutical ingredients (APIs), traditional Chinese medicine (TCM) derivatives, and various other related products across China. The company's pharmaceutical portfolio includes an array of licorice-based items: Gan Di Xin, an oral medication for cough and expectorant relief; Q…